Napredna pretraga

Pregled bibliografske jedinice broj: 176266

Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse


Lovrić-Benčić, Martina; Sikirić, Predrag; Hanzevački, Jadranka S.; Seiwerth, Sven; Rogić, Dunja; Kušec, Vesna; Aralica, Gorana; Konjevoda, Paško; Batelja, Lovorka; Boban-Blagaić, Alenka
Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse // Journal of pharmacological sciences, 95 (2004), 1; 19-26 doi:10.1254/jphs.95.19 (međunarodna recenzija, članak, znanstveni)


Naslov
Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse

Autori
Lovrić-Benčić, Martina ; Sikirić, Predrag ; Hanzevački, Jadranka S. ; Seiwerth, Sven ; Rogić, Dunja ; Kušec, Vesna ; Aralica, Gorana ; Konjevoda, Paško ; Batelja, Lovorka ; Boban-Blagaić, Alenka

Izvornik
Journal of pharmacological sciences (1347-8613) 95 (2004), 1; 19-26

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Pentadecapeptide BPC157; Big endothelin-1; Doxorubicine-congestive heart failure; Amlodipine; Losartan

Sažetak
Overall, doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice ; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period) is consistently deteriorating throughout next 14 days, if not reversed or ameliorated by therapy (/kg per day): a stable gastric pentadecapeptide BPC157 (GEPPPGKPADDAGLV, MW 1419, promisingly studied for inflammatory bowel disease (Pliva ; PL 10, PLD-116, PL 14736)) (10 microg, 10 ng), losartan (0.7 mg), amlodipine (0.07 mg), given intragastrically (i.g.) (once daily, rats) or in drinking water (mice). Assessed were big endothelin-1 (BET-1) and plasma enzyme levels (CK, MBCK, LDH, AST, ALT) before and after 14 days of therapy and clinical status (hypotension, increased heart rate and respiratory rate, and ascites) every 2 days. Controls (distilled water (5 ml/kg, i.g., once daily) or drinking water (2 ml/mouse per day) given throughout 14 days) exhibited additionally increased BET-1 and aggravated clinical status, while enzyme values maintained their initial increase. BPC157 (10 microg/kg) and amlodipine treatment reversed the increased BET-1 (rats, mice), AST, ALT, CK (rats, mice), and LDH (mice) values. BPC157 (10 ng/kg) and losartan opposed further increase of BET-1 (rats, mice). Losartan reduces AST, ALT, CK, and LDH serum values. BPC157 (10 ng/kg) reduces AST and ALT serum values. Clinical status of CHF-rats and -mice is accordingly improved by the BPC157 regimens and amlodipine.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati